The Dr Reddy’s share price plunged 5.6% to an intra-day low of Rs 1,180.90 on the National Stock Exchange as soon as markets opened on Thursday, October 30. The fall in the stock price came after the company received a Notice of Non-Compliance (NON) from the Pharmaceutical Drugs Directorate, Canada, regarding its Abbreviated New Drug Submission (ANDS) for Semaglutide Injection.

“The NON outlines requests for additional information & clarifications on specific aspects of the submission. We will submit a response at the earliest and well within the stipulated time period. We remain confident in the quality, safety and comparability of our proposed product and remain committed to making this important therapy available to patients in Canada and other markets at the earliest,” said Dr Red

See Full Page